Liver Fibrosis Device Progress & FY26 Portfolio Webinar
Filed with ASX · · 17 pages · English
Summary by 6ix AI
Resonance Health Ltd has released an investor presentation regarding the progress of its MRI Liver Fibrosis Device and its portfolio for the upcoming fiscal year. The announcement invites investors to a live webinar hosted by the company's executives to discuss key milestones and developments. The presentation outlines the company's innovative non-invasive technology aimed at improving liver fibrosis diagnostics, addressing significant market needs. It highlights the potential of the device in a growing diagnostics market, emphasizing its advantages over traditional biopsy methods.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Resonance Health
- Profit Guidance Upgrade
- Receipt of R&D Tax Incentive Refund
- Half Year Results Presentation
- Half Year Results
- Half Year Report & Accounts
Later from Resonance Health
- FY26 Full Year Results & Investor Webinar
- Global Strategic Alliance & MSA with Image Analysis Group
- Trading Halt
- Liver Fibrosis Device - EPoC Study Results
- $6.0 Million Placement Oversubscribed
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health